Biological Therapeutics Product Development Subject Matter Expert Consulting Services to Support the Development of Therapeutic Biotechnology Products (Biologics)
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded Voisin Consulting, Inc. a $3,770,592 labor-hour contract to provide biological therapeutics product development subject matter expert consulting services in support of the agency's development of therapeutic biotechnology products. The competitive award was issued following a solicitation and will utilize Voisin Consulting's expertise over an unspecified period of time to assist the National Institute on Drug Abuse in advancing its portfolio of biologic therapeutics.
75N95022P00212 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
4/15/22, 12:04 PM Biological Therapeutics Product Development Subject Matter Expert Consulting Services to Support the Development of Therapeutic Biotechnology Products (Biologics)
Shabas Solutions, LLC was awarded a $502,200 labor-hour contract by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to provide biological therapeutics product development subject matter expert consulting services to support the development of therapeutic biotechnology products over an unspecified period of performance. The contract was awarded on April 15, 2022 following a competitive solicitation to utilize the contractor's expertise and assist the agency with biologics-related initiatives.
75N95022P00201 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
4/15/22, 12:01 PM Biological Therapeutics Product Development Subject Matter Expert Consulting Services to Support the Development of Therapeutic Biotechnology Products (Biologics)
The National Institute of Neurological Disorders and Stroke seeks to procure biological therapeutics product development subject matter expert consulting services through December 2024 to provide technical recommendations and advice supporting novel biologics development programs at the National Institutes of Health. Consultants are required across eight subject matter areas including biologics development, manufacturing, and clinical trials to assist initiatives such as the Blueprint Neurotherapeutics Network Biologics program. Proposals will be evaluated in two phases on personnel qualifications, technical approach, and pricing, with quotes due by November 12, 2021 for the labor-hour contract.
The solicitation is a total small business set-aside under NAICS code 541690 with a size standard of $16.5 million average annual receipts. Evaluation will utilize criteria on key personnel experience and technical presentations, with the agency seeking up to three experts annually in each area for estimated 20 hours each up to a maximum of 800 hours per expert. Potential award value depends on the number of subject matter experts proposed across the defined areas to support candidate biologics development, cGMP manufacturing, and clinical trials advice for conditions of the nervous system through December 2024. Place of performance is the contractor's site and various NIH locations.
NIH-NINDS-CSS-22-000015 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
10/29/21, 6:06 PM Biological Therapeutics Product Development Subject Matter Expert Consulting Services to Support the Development of Therapeutic Biotechnology Products (Biologics)
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $1,894,800 labor-hour contract to PharmaLex US Corporation to provide biological therapeutics product development subject matter expert consulting services to support the development of therapeutic biotechnology products. The contract was awarded on a labor-hour basis following a competitive solicitation process, as the required level of effort for the services could not be reasonably estimated, making a fixed-price contract inappropriate.
75N95022P00209 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
4/15/22, 12:07 PM